Driving Innovation in Addiction Research & Solutions Forward

Name: Taos Therapeutics
Address: Madison Square Park, New York, NY

The time for safe, humane & effective agonist treatment for Alcohol Use Disorder is now

New York, New York USA

The time for safe, humane & effective agonist treatment for Alcohol Use Disorder is now

New York, New York USA

About Taos Therapeutics

Taos Therapeutics is developing the first agonist + guardrail therapy with digital adherence for Alcohol Use Disorder (AUD), a disease killing ~178,000 Americans annually — significantly more than opioids and stimulants together.
Our pioneering new approach combines rx's & a smart device to deter relapse while simultaneously addressing the fundamental neurobiology of AUD for the first time.
With ~14 million U.S. adults affected and <3% receiving pharmacotherapy, the market opportunity is massive, and payer reimbursement models are already proven in opioid addiction.
We are pursuing a 505(b)(2) FDA pathway leveraging existing safety data, with clear 6–12 month de-risking milestones and accelerated approval.
This is a transformational, first-in-class therapy with a direct line to M&A or IPO exit as the new standard of care for AUD.